Kurpiewska Dominika, Kośnik Artur, Bieliński Krzysztof, Raszeja-Wyszomirska Joanna
Department of Hepatology, Transplantology and Internal Medicine, Medical University of Warsaw, Banacha 1A Str., 02-097 Warsaw, Poland.
J Clin Med. 2025 May 18;14(10):3539. doi: 10.3390/jcm14103539.
Acute-on-chronic liver failure (ACLF) is a complex and severe condition marked by multiple organ failure and high short-term mortality. Coagulopathy, a key component of ACLF, is characterized by rebalanced hemostasis with both hypo- and hypercoagulable features, increasing the risk of bleeding and thrombosis. Conventional coagulation tests, including prothrombin time (PT) and platelet count, fail to fully capture the complexity of coagulation dysfunction in ACLF. Advanced diagnostic tools, like viscoelastic tests (VETs), offer a more comprehensive assessment, yet they remain limited in evaluating endothelial dysfunction and fail to account for reduced levels of anticoagulant factors. Emerging therapeutic strategies targeting coagulopathies in ACLF hold promise, but their clinical efficacy remains unclear. A more nuanced approach to diagnosing and managing coagulopathy in ACLF is needed, incorporating advanced hemostatic profiling to better inform prognosis and guide treatment decisions.
慢加急性肝衰竭(ACLF)是一种复杂且严重的病症,其特征为多器官功能衰竭以及短期死亡率高。凝血功能障碍是ACLF的一个关键组成部分,其特点是止血功能失衡,同时具有低凝和高凝特征,增加了出血和血栓形成的风险。传统凝血检测,包括凝血酶原时间(PT)和血小板计数,无法完全捕捉ACLF中凝血功能障碍的复杂性。先进的诊断工具,如粘弹性检测(VETs),可提供更全面的评估,但在评估内皮功能障碍方面仍存在局限性,且未考虑抗凝因子水平降低的情况。针对ACLF中凝血功能障碍的新兴治疗策略具有前景,但其临床疗效仍不明确。需要一种更细致入微的方法来诊断和管理ACLF中的凝血功能障碍,纳入先进的止血分析,以更好地为预后提供信息并指导治疗决策。